At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
LAS100977 0.313 μg +6 moredrug
Likely dose
LAS100977 0.313 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.
In Brief
A Phase 2 clinical trial evaluating LAS100977 0.313 μg, LAS100977 0.625 μg, and 5 other interventions for Asthma. Completed, enrolled 62 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionFeb 2012
TodayJul 2026
First PostedAug 30, 2011
Enrollment StartAug 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.8 years ago
Interventions
LAS100977 0.313 μgdrug
Dry powder inhalation, once-daily, single-dose
LAS100977 0.625 μgdrug
Dry powder inhalation, once-daily, single-dose
LAS100977 1.25 μgdrug
Dry powder inhalation, once-daily, single-dose
LAS100977 2.5 μgdrug
Dry powder inhalation, once-daily, single-dose
Salbutamol 400 μgdrug
Pressurized inhalation suspension, once-daily, single-dose
Salbutamol placebodrug
Pressurized inhalation, once-daily
LAS100977 placebodrug
Dry powder inhalation, once-daily